Brooklyn ImmunoTherapeutics to Present at the Access to Giving Virtual Investor Conference on July 15, 2021

Rhea-AI Summary

Brooklyn ImmunoTherapeutics (NYSE American: BTX) announced that CEO Howard J. Federoff will present at the Access to Giving Virtual Investor Conference from July 13-15, 2021. His presentation is scheduled for July 15 at 9:00 AM ET. The company focuses on cytokine and gene editing therapies for cancer and other diseases. Notably, their leading program, IRX-2, is under evaluation for safety and efficacy in treating head and neck cancer, showing promising overall survival benefits in a Phase 2A trial. Further studies are anticipated for other solid tumor indications.

NEW YORK, July 12, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics LLC (NYSE American: BTX) (“Brooklyn” or “the Company”), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announced that Chief Executive Officer Howard J. Federoff, M.D., Ph.D., will present a corporate overview at the Access to Giving Virtual Investor Conference being held July 13 – 15, 2021.

Dr. Federoff will deliver his corporate presentation on July 15 at 9:00am ET.

To receive additional information, request an invitation or to schedule a one-on-one meeting, please email angie.goertz@issuerdirect.com.

Investors can register here.

About Brooklyn ImmunoTherapeutics
Brooklyn is focused on exploring the role that cytokine-based therapy can have in treating patients with cancer, both as a single agent and in combination with other anti-cancer therapies. The company is also exploring opportunities to advance therapies using leading edge gene editing/cell therapy technology through its option agreement with Factor Bioscience/Novellus.

Brooklyn’s most advanced program is studying the safety and efficacy of IRX-2 in patients with head and neck cancer. In a Phase 2A clinical trial in head and neck cancer, IRX-2 demonstrated an overall survival benefit. Additional studies are either underway or planned in other solid tumor cancer indications.

For more information about Brooklyn and its clinical programs, please visit www.BrooklynITx.com.

Investor Relations Contact:
CORE IR
516-222-2560
investors@brooklynitx.com

Media Contact:
Jules Abraham
CORE IR
917-885-7378
julesa@coreir.com

FAQ

When is the Brooklyn ImmunoTherapeutics CEO presentation at the Access to Giving Virtual Investor Conference?

Howard J. Federoff will present on July 15, 2021, at 9:00 AM ET.

What is the focus of Brooklyn ImmunoTherapeutics?

The company focuses on cytokine and gene editing therapies for cancer, blood disorders, and monogenic diseases.

What is the latest clinical program from Brooklyn ImmunoTherapeutics?

The company's most advanced program is IRX-2, which is being studied for head and neck cancer.

What were the results of the Phase 2A clinical trial for IRX-2?

IRX-2 demonstrated an overall survival benefit in patients with head and neck cancer during the Phase 2A trial.

How can investors learn more about Brooklyn ImmunoTherapeutics?

Investors can visit www.BrooklynITx.com for more information about the company's clinical programs.